Crossmark

Rare exon 18 G719A and exon 21 L833V compound EGFR mutations show favorable response to Third-Generation TKI Furmonertinib: A case report and literature review

Crossref DOI link: https://doi.org/10.1007/s10637-025-01521-y

Published Online: 2025-03-27

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yuejian,

Zhao, Jijun

Wu, Tao

Zhang, Dongdong
Funding

Funding for this research was provided by:

Platform Special Fund for Scientific Research of Xiangyang No.1 People’s Hospital (XYY2022P05)

Innovative Research Program of Xiangyang No.1 People's Hospital (XYY2023SD06 and XYY2023QB07)
License Information

Text and Data Mining valid from 2025-03-27

Version of Record valid from 2025-03-27
More Information

Article History

Received: 10 February 2025

Accepted: 3 March 2025

First Online: 27 March 2025

Declarations

:

: This study was approved by the Ethics and Scientific Committee of Hubei University of Medicine with approval number 2022PR-H002. Written informed consent was obtained from the individual for the publication of any potentially identifiable images included in this article.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below